Displaying 1 - 20 of 1594
FTC Files Amicus Brief in Sage Chemical vs. Supernus Pharmaceutical Supporting Competition in the Market for Drug Used to Treat Advanced Parkinson’s Disease
FTC and Justice Department to Hold Annual Spring Enforcers Summit
FTC Takes Action Against Another Company That Imposed Harmful Noncompete Restrictions on Its Workers
Dissenting Statement of Commissioner Christine S. Wilson In the Matter of Anchor Glass Container Corp
FTC Submits Annual Budget Request to Congress
FTC Acts to Block Deal Combining the Two Top Mortgage Loan Technology Providers
FTC Approves Final Order Requiring Michigan-Based Security Companies to Drop Noncompete Restrictions That They Imposed on Workers
FTC Extends Public Comment Period on Its Proposed Rule to Ban Noncompete Clauses Until April 19
Illumina, Inc., and GRAIL, Inc., In the Matter of
The Federal Trade Commission filed an administrative complaint and authorized a federal court lawsuit to block Illumina’s $7.1 billion proposed acquisition of Grail—a maker of a non-invasive, early detection liquid biopsy test that can screen for multiple types of cancer in asymptomatic patients at very early stages using DNA sequencing. Illumina is the only provider of DNA sequencing that is a viable option for these multi-cancer early detection, or MCED, tests in the United States.
The complaint alleges the proposed acquisition will diminish innovation in the U.S. market for MCED tests, which could be used to detect up to 50 types of cancer. Most of these types of cancer are not screened for at all today, and the MCED test could save millions of lives around the world. The trial began on Aug. 24, 2021. On May 20, 2021, the FTC authorized staff to dismiss its federal court complaint for Preliminary Injunction and Temporary Restraining Order.
Altria Group/JUUL Labs, In the Matter of
The Federal Trade Commission filed an administrative complaint alleging that Altria Group, Inc. and JUUL Labs, Inc. entered a series of agreements, including Altria’s acquisition of a 35% stake in JUUL, that eliminated competition in violation of federal antitrust laws. According to the complaint, this series of agreements involved Altria ceasing to compete in the U.S. market for closed-system electronic cigarettes in return for a substantial ownership interest in JUUL, by far the dominant player in that market. In an initial decision announced on Feb. 24, 2022, Chief Administrative Law Judge D. Michael Chappell dismissed the antitrust charges in the complaint.
Statement of Commissioner Alvaro M. Bedoya Joined by Commissioner Rebecca Kelly Slaughter Regarding Amazon.com, Inc.'s Acquisition of 1Life Healthcare, Inc.
FTC Approves Final Orders Requiring Two Glass Container Manufacturers to Drop Noncompete Restrictions That They Imposed on Workers
Ardagh Group, et al., In the Matter of
O-I Glass, Inc., In the Matter of
FTC and Justice Department Host Asia-Pacific Economic Cooperation Workshop on Competition Advocacy
Statement of Elizabeth Wilkins, Director of the FTC’s Office of Policy Planning, on the Decision of SUNY Upstate Medical University and Crouse Health System, Inc. to Drop Their Proposed Merger
FTC to Host Forum on February 16 Examining Its Proposed Rule to Ban Noncompete Restrictions
Displaying 1 - 20 of 1594